Samuel Ray Denmeade, MD

Aggarwal, S.; Harden, J.L.; Denmeade, S.R. Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach. Bioconjug Chem. 2006 Mar-Apr;17(2):335-340.

Aggarwal, S.; Ricklis, R.M.; Williams, S.A.; Denmeade, S.R. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate. 2006 Jun 15;66(9):903-910.

Aggarwal, S.; Singh, P.; Topaloglu, O.; Isaacs, J.T.; Denmeade, S.R. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 2006 Sep 15;66(18):9171-9177.

Janssen, S.; Rosen, D.M.; Ricklis, R.M.; Dionne, C.A.; Lilja, H.; Christensen, S.B.; Isaacs, J.T.; Denmeade, S.R. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate. 2006 Mar 1;66(4):358-368.

Liu, H.; Jensen, K.G.; Tran, L.M.; Chen, M.; Zhai, L.; Olsen, C.E.; Sohoel, H.; Denmeade, S.R.; Isaacs, J.T.; Brogger Christensen, S. Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica. Phytochemistry. 2006 Dec;67(24):2651-2658.

Singh, P.; Uzgare, A.; Litvinov, I.; Denmeade, S.R.; Isaacs, J.T. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocrine-related cancer. 2006 Sep;13(3):653-666.

Sinibaldi, V.J.; Elza-Brown, K.; Schmidt, J.; Eisenberger, M.A.; Rosenbaum, E.; Denmeade, S.R.; Pili, R.; Walczak, J.; Baker, S.D.; Zahurak, M.; Carducci, M.A. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. American journal of clinical oncology. 2006 Aug;29(4):395-398.

Sohoel, H.; Jensen, A.M.; Moller, J.V.; Nissen, P.; Denmeade, S.R.; Isaacs, J.T.; Olsen, C.E.; Christensen, S.B. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorganic & medicinal chemistry. 2006 Apr 15;14(8):2810-2815.

Strock, C.J.; Park, J.I.; Rosen, D.M.; Ruggeri, B.; Denmeade, S.R.; Ball, D.W.; Nelkin, B.D. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab. 2006 Jan;91(1):79-84.

Xu, Y.; Dalrymple, S.L.; Becker, R.E.; Denmeade, S.R.; Isaacs, J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-4079.

Bajaj, G.K.; Zhang, Z.; Garrett-Mayer, E.; Drew, R.; Sinibaldi, V.; Pili, R.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.; DeWeese, T.L. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar;69(3):526-531.

Chandran, S.S.; Nan, A.; Rosen, D.M.; Ghandehari, H.; Denmeade, S.R. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol Cancer Ther. 2007 Nov;6(11):2928-2937.

Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.; Denmeade, S.R. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biol Ther. 2007 Jun 5;6(9).

Kachhap, S.K.; Faith, D.; Qian, D.Z.; Shabbeer, S.; Galloway, N.L.; Pili, R.; Denmeade, S.R.; DeMarzo, A.M.; Carducci, M.A. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS ONE. 2007;2(9):e844.

Kumar, S.K.; Williams, S.A.; Isaacs, J.T.; Denmeade, S.R.; Khan, S.R. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorganic & medicinal chemistry. 2007 Jul 15;15(14):4973-4984.

Singh, R.; Browning, J.L.; Abi-Habib, R.; Wong, K.; Williams, S.A.; Merchant, R.; Denmeade, S.R.; Buckley, T.J.; Frankel, A.E. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anti-cancer drugs. 2007 Aug;18(7):809-816.

Williams, S.A.; Merchant, R.F.; Garrett-Mayer, E.; Isaacs, J.T.; Buckley, J.T.; Denmeade, S.R. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 7;99(5):376-385.

Williams, S.A.; Singh, P.; Isaacs, J.T.; Denmeade, S.R. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate. 2007 Feb 15;67(3):312-329.

Aggarwal, S.; Brennen, W.N.; Kole, T.P.; Schneider, E.; Topaloglu, O.; Yates, M.; Cotter, R.J.; Denmeade, S.R. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 2008 Jan 22;47(3):1076-1086.

Chandran, S.S.; Banerjee, S.R.; Mease, R.C.; Pomper, M.G.; Denmeade, S.R. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer biology & therapy. 2008 Jun;7(6):974-982.

Denmeade, S.R. Prostate Speific Membrane Antigen. Encyclopedia of Cancer; 2008. p. In Press.
Denmeade, S.R. Androgens. In: R. C. Bast, D.W.K., R. E Pollock, R. R. Weichelbaum, J. F. Holland, and E. Frei, editor. Vol. In Press., Cancer Medicine. Hamilton, Ontario: B. C. Decker, Inc.; 2008.

LeBeau, A.M.; Singh, P.; Isaacs, J.T.; Denmeade, S.R. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem Biol. 2008 Jul 21;15(7):665-674.

Pili, R., J. Walczak, M. A. Carducci, and S. R. Denmeade. Genitourinary Cancer. In: Donhower, D.E.a.R., editor, Current Cancer in Therapeutics. Philadelphia: Current Medicine Group; 2008.

Rathkopf, D.; Carducci, M.A.; Morris, M.J.; Slovin, S.F.; Eisenberger, M.A.; Pili, R.; Denmeade, S.R.; Kelsen, M.; Curley, T.; Halter, M.; Collins, C.; Fleisher, M.; Heller, G.; Baker, S.D.; Scher, H.I. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959-2965.

Singh, P.; Williams, S.A.; Shah, M.H.; Lectka, T.; Pritchard, G.J.; Isaacs, J.T.; Denmeade, S.R. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Proteins. 2008 Mar;70(4):1416-1428.

Singla, A.; Denmeade, S.R. Left posterior fascicular block due to high-dose interleukin-2. The Annals of pharmacotherapy. 2008 Sep;42(9):1340-1343.

Chandran, S.S.; Williams, S.A.; Denmeade, S.R. Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivo. Luminescence. 2009 Jan-Feb;24(1):35-38.

Christensen, S.B.; Skytte, D.M.; Denmeade, S.R.; Dionne, C.; Moller, J.V.; Nissen, P.; Isaacs, J.T. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Med Chem. 2009 Mar;9(3):276-294.

Gustin, J.P.; Karakas, B.; Weiss, M.B.; Abukhdeir, A.M.; Lauring, J.; Garay, J.P.; Cosgrove, D.; Tamaki, A.; Konishi, H.; Konishi, Y.; Mohseni, M.; Wang, G.; Rosen, D.M.; Denmeade, S.R.; Higgins, M.J.; Vitolo, M.I.; Bachman, K.E.; Park, B.H. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-2840.

LeBeau, A.M.; Banerjee, S.R.; Pomper, M.G.; Mease, R.C.; Denmeade, S.R. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorganic & medicinal chemistry. 2009 Jul 15;17(14):4888-4893.

LeBeau, A.M.; Brennen, W.N.; Aggarwal, S.; Denmeade, S.R. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther. 2009 May 5;8:1378-1386.

LeBeau, A.M.; Singh, P.; Isaacs, J.T.; Denmeade, S.R. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry. 2009 Apr 21;48(15):3490-3496.

Lin, J.; Denmeade, S.; Carducci, M.A. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Current cancer drug targets. 2009 Nov;9(7):881-887.

Lin, J.; Sinibaldi, V.J.; Carducci, M.A.; Denmeade, S.; Song, D.; Deweese, T.; Eisenberger, M.A. Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2009 Dec 3.

Sharma, P.; Wisniewski, A.; Braga-Basaria, M.; Xu, X.; Yep, M.; Denmeade, S.; Dobs, A.S.; DeWeese, T.; Carducci, M.; Basaria, S. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol. 2009 Nov;182(5):2265-2272.

Singh, P.; LeBeau, A.M.; Lilja, H.; Denmeade, S.R.; Isaacs, J.T. Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins. 2009 Dec;77(4):984-993.

Taplin, M.E.; Regan, M.M.; Ko, Y.J.; Bubley, G.J.; Duggan, S.E.; Werner, L.; Beer, T.M.; Ryan, C.W.; Mathew, P.; Tu, S.M.; Denmeade, S.R.; Oh, W.K.; Sartor, O.; Mantzoros, C.S.; Rittmaster, R.; Kantoff, P.W.; Balk, S.P. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15;15(22):7099-7105.

Vander Griend, D.J.; Antony, L.; Dalrymple, S.L.; Xu, Y.; Christensen, S.B.; Denmeade, S.R.; Isaacs, J.T. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther. 2009 May 5;8(5):1340-1349.

Danila, D.C.; Morris, M.J.; de Bono, J.S.; Ryan, C.J.; Denmeade, S.R.; Smith, M.R.; Taplin, M.E.; Bubley, G.J.; Kheoh, T.; Haqq, C.; Molina, A.; Anand, A.; Koscuiszka, M.; Larson, S.M.; Schwartz, L.H.; Fleisher, M.; Scher, H.I. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20;28(9):1496-1501.

Denmeade, S.R.; Egerdie, B.; Steinhoff, G.; Merchant, R.; Abi-Habib, R.; Pommerville, P. Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2010 Nov 24;Epub 12/7/10.

Denmeade, S.R.; Isaacs, J.T. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010 Oct 1;70(14):1600-1607.

Hu, R.; Denmeade, S.R.; Luo, J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab. 2010 Sep;5(5):753-764.

Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.

Weiss, M.B.; Vitolo, M.I.; Mohseni, M.; Rosen, D.M.; Denmeade, S.R.; Park, B.H.; Weber, D.J.; Bachman, K.E. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene. 2010 Aug 19;29(33):4715-4724.

Brandy, Y.; Ononiwu, I.; Adedeji, D.; Williams, V.; Mouamba, C.; Kanaan, Y.; Copeland, R.L., Jr.; Wright, D.A.; Butcher, R.J.; Denmeade, S.R.; Bakare, O. Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines. Invest New Drugs. 2011 Jan 18;Epub 1/19/11.